AI assistant
Passage BIO, Inc. — Director's Dealing 2021
Jul 22, 2021
34849_dirs_2021-07-21_bccad7cf-3d74-4475-b370-549568dca6a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2021-07-19
Reporting Person: Toernsen Monika Maria (Chief Commercial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-19 | Employee Stock Option (Right to Buy) | $13.04 | A | 200000 | Acquired | 2031-07-18 | Common Stock (200000) | Direct |
| 2021-07-19 | Restricted Stock Units | $ | A | 20000 | Acquired | Common Stock (20000) | Direct |
Footnotes
F1: The option vests as to 25% of the total shares on July 19, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on July 19, 2024, subject to the Reporting Person's provision of service to the issuer on each vesting date.
F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3: 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.